Hodgkin's relapse for 'Survivor' winner Zohn
After twenty months of remission, television reality show winner Ethan Zohn has learned that his Hodgkin's lymphoma has relapsed.
The disease has apparently been found to have localized in his chest. Despite this setback, Zohn, who has become a motivational speaker and philanthropist, will still run in the upcoming New York City Marathon.
Zohn has indicated that for treatment this time, his doctors may give him Adcetris (formerly known as SGN-35), the Seattle Genetics HL treatment approved this past August by the FDA for specific indications within both Hodgkin's and Anaplastic Large Cell Lymphoma.
Zohn and his doctors have also discussed the possibility of a bone marrow transplant.
Source: Los Angeles Times
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
